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Abstract. Theaflavin-3, 3'-digallate (TF3) is a black tea poly-
phenol produced from polymerization and oxidization of the 
green tea ployphenols epicatechin gallate and (-)-epigallocate-
chin-3-gallate (EGCG) during fermentation of fresh tea leaves. 
TF3 has been reported to have anticancer properties. However, 
the effect of TF3 on tumor angiogenesis and the underlying 
mechanisms are not clear. In the present study, TF3 was veri-
fied to inhibit tumor angiogenesis. Compared with EGCG, 
TF3 was more potent. TF3 inhibited human ovarian carcinoma 
OVCAR-3 cell-induced angiogenesis in human umbilical vein 
endothelial cell model and in chick chorioallantoic membrane 
model. TF3 reduced tumor angiogenesis by downregulating 
HIF-1α and VEGF. One of the mechanisms was TF3 inacti-
vated Akt/mTOR/p70S6K/4E-BP1 pathway and Akt/c-Myc 
pathway. Besides, TF3 suppressed the cleavage of Notch-1, 
subsequently decreased the expression of c-Myc, HIF-1α 
and VEGF, and finally the impaired cancer cells induced 
angiogenesis. Nevertheless, TF3 did not have any influence on 
the MAPK pathways. Taken together, these findings suggest 
that TF3 might serve as a potential anti-angiogenic agent for 
cancer treatment.
Introduction
Epithelial ovarian cancer is the most lethal gynecological 
cancer (1). Cytoreductive surgery with chemotherapy is the 
standard of care for ovarian cancer (2). However, 20-40% 
of patients do not respond to first-line chemotherapy (3). 
Furthermore, a large proportion of patients will have a relapse 
of the disease within 5 years (1), especially those in advanced 
stage. Unfortunately, recurrence is typically less responsive to 
current chemotherapeutic strategies (1).
Angiogenesis plays an important role in the growth and 
progression of solid tumors (4). Tumor angiogenesis is charac-
terized by the formation of new irregular blood vessels from 
a preexisting vascular network (5). Tumor vasculature usually 
has poor blood flow and high vascular permeability, which 
may lead to decreased efficiency of cytotoxic chemotherapy 
and increased potential for metastasis (6). Angiogenesis can 
be regulated by many signaling molecules and growth factors, 
including vascular endothelial growth factor (VEGF). VEGF 
is a crucial factor in modulating multiple vascular steps. VEGF 
expression can be upregulated by hypoxia-inducible factor 1 
(HIF-1). HIF-1 is a basic-loop helix PER-ARNT-SIM tran-
scription factor consisting of two subunits, HIF-1α and HIF-1β. 
Overexpression of HIF-1α has been demonstrated in >70% of 
human cancers and metastases compared to adjacent normal 
tissue (7). Stabilization and upregulation of HIF-1α promotes 
the expression of VEGF by binding to HIF-responsive elements 
in promoters. Therefore, anti-angiogenic agents targeting 
HIF-1α and VEGF are highlighted for anticancer treatment.
Black tea is one of the most popular beverages worldwide. 
Basic procedures of making black tea include withering, 
rolling, fermentation, and drying. During the fermentation 
process, green tea polyphenols are polymerized and oxidized 
to form oligomeric flavanols, such as theaflavins, thearubigin 
and other oligomers (8). Thus black tea has low tea catechin 
content (9). Theaflavins account for 2-6% of the dry weight of 
solids in brewed black tea (9). Theaflavin-3, 3'-digallate (TF3) 
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(Fig. 1A) is one of the four main theaflavins in black tea, which 
is produced by the oxidative dimerization of epicatechin 
gallate (ECG) and (-)-epigallocatechin-3-gallate (EGCG). 
TF3 is a potent anticancer agent. It showed inhibitory effects 
on the growth of various human cancer cells (10). It induced 
apoptosis and cell cycle arrest in cancer cells by generating 
reactive oxygen species and/or modulating signaling path-
ways (8,11,12). Recently, theaflavins were observed to exhibit 
anti-angiogenic activities. TF3 inhibited tube formation in 
cocultured endothelial cells with fibroblasts (13). In human 
prostate cancer-bearing athymic nude mice, theaflavins 
significantly diminished the expression of VEGF in tumors 
(14). Nevertheless, the mechanisms remain unclear.
In the present study, the antitumor-induced angiogenic 
effect and mechanisms of TF3 were investigated. TF3 
impaired human ovarian carcinoma OVCAR-3 cell-induced 
angiogenesis. Part of the underlying mechanisms was TF3 
targeted Akt/mTOR/p70S6K/4E-BP1 pathway, Akt/c-Myc 
pathway and Notch-1/c-Myc pathway to regulating HIF-1α and 
VEGF expression in OVCAR-3 cells. Our study suggests that 
TF3 can be regarded as a candidate anti-angiogenic agent for 
the adjunctive therapy of cancer.
Materials and methods
Cell cultures and reagents. Human ovarian carcinoma cell 
line OVCAR-3, a kind gift from Dr Bing-Hua Jiang, Thomas 
Jefferson University, was cultured in RPMI-1640 medium 
(Sigma, St. louis, MO, USA) incorporating 10% fetal bovine 
serum (FBS) (Invitrogen, Grand Island, Ny, USA). Human 
umbilical vein endothelial cells (HUVECs), purchased from 
American Type Culture Collection (ATCC, Manassas, VA, 
USA), were maintained in F-12K medium (ATCC) supple-
mented with 10% FBS (Invitrogen) and Endothelial Cell 
Growth Kit-VEGF (ATCC). Cells were grown in a humidified 
incubator containing 5% CO2 at 37˚C.
Reagents: TF3 monomer (purity: 92.4%) was isolated 
and purified using previously established method (15). 
Wortmannin and N-[N-(3,5-difluorophenacetyl)-l-alanyl]-
S-phenylglycine t-butyl ester (DAPT) were purchased 
from Sigma and Santa Cruz Biotechnology (Santa Cruz, 
CA, USA), respectively. Antibodies against phospho-Akt 
(Ser473) (p-Akt), Akt, phospho-p70S6 kinase (Thr421/Ser424) 
(p-p70S6K), p70S6K, eukaryotic initiation factor 4E-binding 
protein-1 (4E-BP1), HIF-1α, Notch-1, c-Jun N-terminal 
kinases (JNK), p38 and phosphor-Forkhead Box O1 (Thr24) 
(p-FoxO1) were purchased from Cell Signaling Technology, 
Inc. (Danvers, MA, USA). Antibodies against phosphor-
mammalian target of rapamycin (p-mTOR) (Ser2448), mTOR 
were purchased from R&D Systems (Minneapolis, MN, 
USA). Antibodies against phosphor-4E-BP1 (Ser65/Thr70) 
(p-4E-BP1), c-Myc, phosphor-extracellular signal-regulated 
kinases 1/2 (Thr202/Tyr204) (p-ERK1/2), ERK1/2 and 
GAPDH were purchased from Santa Cruz Biotechnology Inc. 
(Santa Cruz). Plasmids (myrAkt delta4-129, pcDNA3-Flag 
mTOR wt, pWZl Neo Myr Flag RPS6KB1, pET14b PHAS-I, 
HA-HIF1alpha-pcDNA3, 3XFlagNICD1, pMXs-hc-MyC, 
ODD-luciferase-pcDNA3, VEGF promoter, cMyc promoter 
(TBE1/2-wt), and pCBFRE-luc) were purchased from Addgene 
(Cambridge, MA, USA).
Cell viability assay. OVCAR-3 cells were seeded into 96-well 
plates at a density of 2x104 per well in medium with 10% FBS. 
After overnight growth, cells were treated with different 
concentrations of TF3 for 24 h. Cell viability was measured 
using CellTiter 96® Aqueous One Solution Cell Proliferation 
assay (Promega, Madison, WI, USA), according to the 
manufacturer's instructions. Cell viability was expressed as a 
percentage compared to control cells (vehicle treatment).
HUVEC tube formation assay. Growth factor-reduced 
Matrigel (50 µl) (BD Biosciences, San Jose, CA, USA) was 
added into each well of a 96-well plate and polymerized for 
30 min at 37˚C. HUVECs (1.5x104/well) in 100 µl conditioned 
medium (90 µl F12-K medium+10 µl cell culture supernatant 
of vehicle or TF3-treated OVCAR-3 cells) were seeded into 
each growth factor-reduced Matrigel-coated well, incubated at 
37˚C in 5% CO2 for 6 h, and photographed under a microscope. 
Tube length was quantified using the NIH ImageJ software 
(NIH, Bethesda, MD, USA). Tube length was expressed as a 
percentage compared to the control group.
Chick chorioallantoic membrane (CAM) assay. Specific 
pathogen-free fertile chicken eggs (Charles River laboratories, 
North Franklin, CT, USA) were incubated at 37.5˚C and slowly 
turned by an automatic egg turner (G.Q.F. Manufacturing 
Co., Savannah, GA, USA). On the 8th day of development of 
fertilized chicken eggs, a 1-cm diameter window was opened 
in the shell of each egg to expose the CAM. On the 9th day, 
106 OVCAR-3 cells in 20 µl FBS-free RPMI-1640 medium 
were mixed with 80 µl Matrigel (BD Biosciences), supple-
mented with TF3 at a final concentration of 25 µmol/l (µM) or 
equivalent vehicle, and implanted onto the CAM. After incu-
bating for another 5 days, tumor implants and blood vessels 
were photographed and counted for branching blood vessels. 
Blood vessel density was normalized to the control group.
Enzyme linked immunosorbent assays. OVCAR-3 cells were 
seeded into 96-well plates at a density of 2x104 per well, incu-
bated overnight and treated with different concentrations of 
TF3 for 24 h. Cell culture supernatants were collected. The 
concentration of human VEGF protein was determined by 
a human VEGF Duo-set ElISA kit (R&D) according to the 
manufacturer's instructions.
Western blot analysis. OVCAR-3 cells were treated for 24 h 
with various concentrations of TF3 in 60 mm dishes, and 
then lysed in 100 µl mammalian protein extraction reagent 
supplemented with Halt™ Protease and Phosphatase Inhibitor 
Single-Use Cocktail (life Technologies, Grand Island, Ny, 
USA). The concentration of protein was measured using a 
BCA Protein assay kit (Thermo, Waltham, MA, USA). Equal 
amounts of protein were prepared and separated by SDS-PAGE 
and transferred onto the nitrocellulose membranes with a 
Mini-Protean 3 system (Bio-Rad, Hercules, CA, USA). The 
membrane was blocked with 5% non-fat milk in Tris-buffer 
saline containing 0.1% Tween-20 for 1 h at room temperature 
and incubated with indicated primary antibodies overnight at 
4˚C followed by horseradish peroxidase-conjugated secondary 
antibody for 2 h at 37˚C. Detection was performed by 
SuperSignal West Dura Extended Duration Substrate (life 
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Technologies) and ChemiDoc™ MP System (Bio-Rad). 
Protein bands were quantified with the NIH ImageJ software 
(NIH), normalized by corresponding GAPDH for analysis.
Transient transfection and luciferase reporter assay. 
OVCAR-3 cells were seeded in 96-well plates at a density 
of 2x104 per well and transfected with plasmids (including 
Figure 1. Theaflavin-3, 3'-digallate (TF3) inhibits OVCAR-3 cell-induced angiogenesis by targeting HIF-1α and VEGF. (A) Molecular structure of TF3. 
(B) Viability of OVCAR-3 cells was decreased after TF3 treatment for 24 h. (C) OVCAR-3 cells-induced HUVEC tube formation was inhibited by TF3 
treatment. (D) OVCAR-3 cell-induced blood vessel development in the CAM model was reduced by TF3 treatment. (E) The protein level of VEGF in TF3-
treated OVCAR-3 cell culture supernatant was reduced. (F) TF3 diminished the transcriptional activity of VEGF promoter, and, overexpression of HIF-1α 
reversed it. The data are presented as the mean ± standard error of mean. *P<0.05 compared with control or between specific groups.
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a targeted gene plasmid, a corresponding luciferase reporter 
plasmid and β-galactosidase control vector) using jetPrimeTM 
DNA and siRNA Transfection reagent (VWR International, 
West Chester, PA, USA). Four hours later, medium was 
replaced by FBS-free RPMI-1640 medium containing TF3 
or equivalent vehicle. Cells were incubated for another 24 h. 
luciferase assays and β-galactosidase assay were performed 
using One-Glo™ luciferase assay system and β-galactosidase 
enzyme assay system (Promega), respectively. luciferase 
activity was expressed relative to β-galactosidase activity.
Statistical analysis. The data are expressed as mean ± standard 
error of mean (SEM) from at least three independent experi-
ments. The results were analyzed with SPSS Version 18.0 for 
Windows (SPSS, Chicago, Il, USA) using one-way analysis of 
variance (ANOVA) and post hoc test (2-sided Dunnett's test) to 
test both overall differences and specific differences between 
each treatment and control. P-values <0.05 were considered 
statistically significant.
Results
TF3 reduces tumor-induced angiogenesis in vitro and in vivo 
by downregulating VEGF and HIF-1α. To evaluate the cyto-
toxicity of TF3 on OVCAR-3 cells, CellTiter 96® Aqueous One 
Solution Cell Proliferation assay was performed (Fig. 1B). TF3 
treatment for 24 h dose-dependently inhibited the viability 
of OVCAR-3 cells, ranging from 100 to 48.3%. The anti-
proliferative activity of TF3 is weak at low concentrations. 
The viability of OVCAR-3 cells was >70% when treated with 
concentrations of 15 µM and below of TF3.
Black tea extracts, which contains theaflavins, has been 
reported to inhibit tumor angiogenesis. To assess whether TF3 
repressed angiogenesis induced by OVCAR-3 cells, HUVEC 
tube formation assay was carried out. HUVECs were cultured 
in F12-K medium supplemented with cell culture supernatant 
of vehicle or TF3-treated OVCAR-3 cells. Mature, intercon-
nected capillary-like networks were observed in the control 
group. However, the tube-like structures found in TF3-treated 
groups were less organized and leaky. Tube length was 
determined to quantify tube formation. The data showed TF3 
interrupted OVCAR-3 cell-induced HUVEC tube formation in 
a dose-dependent manner (Fig. 1C).
To examine the anti-angiogenic potential of TF3 in vivo, 
CAM assay was conducted. Highly vascularized structure was 
found in the control group. TF3 treatment markedly reduced 
blood vessel density. These results confirmed that TF3 inhib-
ited cancer cells induced angiogenesis in vivo (Fig. 1D).
VEGF is an important growth factor involved in tumor 
vascular development and maintenance. We examined the 
effect of TF3 on VEGF secretion using a VEGF ElISA kit. 
The protein level of VEGF in TF3-treated OVCAR-3 cell 
culture supernatant was much lower compared with that in the 
control group. TF3 had an excellent activity on diminishing 
the secretion of VEGF (Fig. 1E), indicating TF3 inhibited 
tumor angiogenesis by targeting VEGF.
HIF-1α has a direct regulatory impact on the expression of 
VEGF. Western blot analysis revealed that TF3 significantly 
Figure 2. Angiogenesis-related proteins are affected by TF3 treatment in OVCAR-3 cells. Western blot analysis revealed that TF3 decreased the protein level of 
p-Akt, p-mTOR, p-p70S6K, p-4E-BP1, Notch-1 (NICD), c-Myc and HIF-1α in OVCAR-3 cells. TF3 had no impact on the protein level of p-ERK1/2, ERK1/2, 
JNK, p38 and p-FoxO 1. GAPDH served as the loading control.
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decreased the protein level of HIF-1α in OVCAR-3 cells 
(Fig. 2). The data of luciferase reporter assay implied TF3 
strongly eliminated the transcriptional activity of VEGF 
promoter. However, this inhibitory effect was abrogated by 
overexpression of HIF-1α (Fig. 1F). It hinted TF3 downregu-
lated VEGF by repressing HIF-1α expression in OVCAR-3 
cells.
TF3 inhibits HIF-1α and VEGF via Akt/mTOR/p70S6K/4E-
BP1 pathway. Previous studies demonstrated that PI3K/Akt 
signaling was required for VEGF expression through HIF-1 in 
response to growth factor stimulation and oncogene activation 
(16). mTOR/p70S6K/RPS6/4E-BP1 signaling pathway also 
played an important role in suppressing HIF-1α and VEGF 
expression (17). To explore whether TF3 decreased HIF-1α and 
VEGF expression via Akt pathway, the protein levels of PTEN, 
p-Akt, Akt, p-mTOR, mTOR, p-p70S6K, p70S6K, p-4E-BP1 
and 4E-BP1 were detected by western blot analysis. As shown 
in Fig. 2, TF3 significantly lowered the protein levels of p-Akt, 
p-mTOR, p-p70S6K and p-4E-BP1. Whereas, the expression 
of PTEN, a negative regulator of the Akt pathway, was not 
affected by TF3 treatment. The result indicated that TF3 inac-
tivated Akt pathway through inhibiting the phosphorylation of 
Akt, mTOR, p70S6K and 4E-BP1 in OVCAR-3 cells.
When treated with TF3 and wortmannin, a selective Akt 
pathway inhibitor, an additive inhibitory effect on Akt pathway 
was observed in OVCAR-3 cells. The protein levels of p-Akt, 
p-mTOR, p-p70S6K, p-4E-BP1, HIF-1α and VEGF in TF3 
and wortmannin co-treated cells were much more reduced 
compared with that in TF3 or wortmannin alone treated cells 
(Fig. 3A and C). Consistent with this, the result of luciferase 
reporter assay validated the transcriptional activity of VEGF 
Figure 3. Akt/mTOR/p70S6k/4E-BP1 pathway and Akt/c-Myc pathway are involved in TF3-induced inhibition of HIF-1α and VEGF. (A) Western blot analysis 
showed that 100 nM wortmannin, 10 µM TF3 and 100 nM wortmannin+10 µM TF3 decreased the phosphorylation of Akt, mTOR, p70S6K and 4E-BP1, and 
expression of c-Myc and HIF-1α. TF3+wortmannin exhibited the strongest effect among them. GAPDH served as the loading control. (B) luciferase reporter 
assay and (C) VEGF ElISA showed 100 nM wortmannin, 10 µM TF3 and 100 nM wortmannin+10 µM TF3 suppressed the transcriptional activity of VEGF 
promoter and VEGF secretion, respectively. TF3+wortmannin elicited strongest effect among them. (D) Overexpression of active Akt attenuated the 15 µM 
TF3-induced decrease of phosphorylation of Akt, mTOR, p70S6K and 4E-BP1, and expression of c-Myc and HIF-1α. 
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Figure 3. Continued. Overexpression of Akt, mTOR, p70S6K or 4E-BP1 attenuated TF3-induced inhibition of transcriptional activity of VEGF promoter (E) 
and HIF-1α promoter (F). (G) Overexpression of active Akt reversed the 15 µM TF3-induced reduction of VEGF secretion. The data are presented as the mean 
± standard error of mean. *P<0.05 compared with control or between specific groups.
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Figure 4. Notch-1/c-Myc pathway is related to TF3-induced inhibition of HIF-1α and VEGF. (A) Western blot analysis showed that 10 µM TF3, 75 µM 
DAPT and 10 µM TF3+75 µM DAPT decreased the expression of NICD, c-Myc and HIF-1α. The dose of 10 µM TF3+75 µM DAPT exhibited the strongest 
effect. GAPDH served as the loading control. (B) luciferase reporter assay and (C) VEGF ElISA showed 10 µM TF3, 75 µM DAPT and 10 µM TF3+75 µM 
DAPT suppressed the transcriptional activity of VEGF promoter and VEGF secretion, respectively. (D) Overexpression of NICD attenuated 15 µM TF3-
induced decrease of NICD, c-Myc and HIF-1α. (E) Overexpression of NICD or c-Myc attenuated TF3-induced inhibition of transcriptional activity of VEGF 
promoter and HIF-1α promoter. (F) Overexpression of NICD or active Akt attenuated TF3-induced inhibition of transcriptional activity of c-Myc promoter. 
(G) Overexpression of NICD reversed the 15 µM TF3-induced reduction of VEGF secretion. The data are presented as the mean ± standard error of mean. 
*P<0.05 compared with control or between specific groups.
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promoter was lower than that in TF3 or wortmannin alone 
treated cells (Fig. 3B). On the contrary, transfected OCVAR-3 
cells with a plasmid expressing constitutively active Akt made 
the cells less responsive to TF3 treatment. TF3-mediated 
decrease in the protein levels of p-Akt, p-mTOR, p-p70S6K, 
p-4E-BP1, HIF-1α and VEGF was partially attenuated in 
Akt-overexpressing OVCAR-3 cells (Fig. 3D and G). Besides, 
transfected cells with plasmid expressing Akt, mTOR, p70S6K 
or 4E-BP1 reversed TF3-induced transcription inhibition of 
VEGF promoter and HIF-1α promoter (Fig. 3E and F). These 
data provided evidence that TF3 reduced HIF-1α and VEGF 
via Akt/mTOR/p70S6K/4E-BP1 pathway in OVCAR-3 cells.
TF3 suppresses HIF-1α and VEGF via Akt/c-myc and 
Notch-1/c-myc pathway. c-Myc is a major human oncogene 
which exerts many biological functions. It has been elucidated 
that c-Myc enhances cancer cell-mediated angiogenesis 
through the regulation of HIF-1α (18). c-Myc expression 
can be regulated in an Akt-dependent manner at the level of 
transcription (19). c-Myc expression also can be affected by 
Notch-1. Notch-1 upregulates c-Myc transcription by directly 
binding to its promoter (20). To investigate whether Akt/c-Myc 
and Notch-1/c-Myc participated in tumor angiogenesis and 
the influence of TF3 on these pathways, western blot analysis 
and luciferase reporter assay were carried out. According to 
the results, TF3 significantly suppressed the expression of 
c-Myc, HIF-1α and VEGF, the cleavage of Notch-1, and the 
phosphorylation of Akt (Figs. 1E and 2). TF3 and wortmannin 
co-treatment enhanced the effect of TF3 on decreasing the 
protein levels of c-Myc, HIF-1α and VEGF (Fig. 3A and C), 
while overexpression of active Akt rescued it (Fig. 3D and G). 
Similarly, exposure to the combination of TF3 and DAPT, 
a Notch inhibitor, caused a stronger repression of c-Myc 
and HIF-1α than DAPT or TF3 alone (Fig. 4A). Whereas, 
overexpression of Notch-1 intracellular domain (NICD) had 
an adverse effect on the TF3-triggered inhibition of c-Myc, 
HIF-1α and VEGF expression (Fig. 4D and G). luciferase 
reporter assay confirmed that wortmannin, DAPT and TF3 
declined the transcriptional activity of VEGF promoter 
(Figs. 3B and 4B). On the contrary, overexpression of active 
Akt or NICD abrogated TF3-induced transcription inhibition 
of c-Myc promoter, HIF-1α promoter and VEGF promoter 
(Figs. 3E and F, and 4E and F). Transfected cells with plasmid 
expressing c-Myc eliminated TF3-induced transcription 
inhibition of HIF-1α and VEGF (Fig. 4E). Taken together, 
Akt/c-Myc/HIF-1α/VEGF pathway and Notch-1/c-Myc/
HIF-1α/VEGF pathway are involved in the antitumor angio-
genic mechanisms of TF3.
TF3 does not affect HIF-1α and VEGF via the MAPK 
pathways. MAPK pathways play essential roles in cell prolif-
eration and differentiation. Activation of MAPK signaling 
pathways has been reported to participate in tumorigenesis, 
metastasis, and angiogenesis of multiple human malignan-
cies (21). To investigate whether TF3 had an influence on 
MAPK pathways, western blot assay was carried out. In this 
study, TF3 showed no sign of affecting the protein levels 
of p-ERK1/2, ERK1/2, JNK, p38 and p-FoxO1 (Fig. 5), 
suggesting MAPK pathways were not relevant to the anti-
tumor angiogenic activity of TF3.
Figure 5. EGCG decreases VEGF secretion of OVCAR-3 cells. (A) Chemical structure of epicatechin gallate. (B) Chemical structure of EGCG. (C) Viability 
and (D) VEGF secretion of EGCG-treated OVCAR-3 cells. All data are presented as the mean ± standard error of mean. *P<0.05 compared with the control 
group.
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Discussion
Ovarian cancer is one of the most common cancers in women. 
Due to the fact that current chemotherapies do not work on a 
proportion of patients and may cause severe side effect, it is 
critical to identify alternative strategies. Some nutrients were 
found to have anticancer activities with little side effect. A 
previous study presented that black tea consumption was asso-
ciated with a linear decline in ovarian cancer risk (22). TF3 is 
produced in black tea manufacturing process. It has multiple 
biological activities, including the anti-oxidant, anti-bacterial, 
anti-obese, and anticancer effects. TF3 inhibits proliferation 
and/or induce apoptosis of various cancer cells (11,12). In this 
study, we tested the cytotoxicity of TF3 on OVCAR-3 cells 
and found TF3 inhibited cell proliferation, especially at high 
concentrations. This is consistent with the former research that 
theaflavins exhibited anti-proliferative and apoptotic activity 
in human teratocarcinoma of ovarian origin (23). Although 
previous studies and the current study proved TF3 exerted an 
anti-proliferative effect of cancer cells, the working concentra-
tions were much higher than the attainable concentrations of 
TF3 in plasma and tissues (24).
Previous studies showed that some food-derived natural 
compounds elicited growth inhibitory activity at higher 
concentrations while anti-angiogenic activity at relatively 
lower concentrations (25,26). Tumor angiogenesis is related 
with poor prognosis in ovarian carcinoma (27). Cancer cells 
can secrete pro-angiogenic factors, including VEGF and basic 
fibroblast growth factor, to stimulate normal endothelial cell 
growth through paracrine mechanisms (28). VEGF regulates 
the key steps of angiogenic process, particularly endothelial 
cell proliferation, survival, permeability, and migration (29). 
TF3 has been demonstrated to inhibit gene expression of VEGF 
in A549 lung cancer cells (30). However, the impact of TF3 on 
ovarian cancer-induced angiogenesis has not been reported yet. 
To explore whether TF3 hampered tumor induced angiogenesis, 
we tested the anti-angiogenic activity of TF3 in the HUVEC 
model and CAM model, and the VEGF protein content in the 
cell culture supernatant of TF3-treated OVCAR-3 cells. In 
this study, TF3 was verified to block OVCAR-3 cell-triggered 
HUVEC tube formation and blood vessel development in 
the CAM model. TF3 started to inhibit HUVEC tube forma-
tion at 5 µM. About half of OVCAR-3 cell-induced HUVEC 
tube formation was blocked after 15 µM TF3 treatment. The 
result of VEGF ElISA was in accordance with that of tube 
formation assay. TF3 strongly reduced the VEGF secretion of 
OVCAR-3 cells. Treatment with 5 µM TF3 caused an ~50% 
decline of VEGF secretion. The data implied that TF3 might 
exert its antitumor angiogenic function by downregulating 
VEGF. It also provided evidence supporting a multifunction 
of TF3 on OVCAR-3 cells between different concentrations. 
In the present study, we also measured the effect of EGCG, 
a precursor of TF3, on VEGF secretion of OVCAR-3 cells. 
EGCG was regarded as one of the most potent bioactives in 
green tea and has been proven to inhibit tumor angiogenesis 
(31). Compared with EGCG, the working concentration of TF3 
was much lower (Fig. 5D). One of the possible reasons might 
be that TF3 was more stable than EGCG in aqueous system 
(pH 7.4) (32). Structural differences might also be responsible 
for this (Figs. 1A and 5B). The activity of tea polyphenols is 
related with the number and position of hydroxyl groups in 
molecules (33). TF3 is produced by the oxidative dimerization 
of ECG and EGCG. Therefore, TF3 contains more hydroxyl 
groups than ECG or EGCG alone.
HIF-1α is a subunit of the heterodimeric transcription 
factor HIF-1, which regulates the transcription of >60 genes, 
including VEGF. Dysregulation and overexpression of HIF-1α 
are heavily implicated in cancer biology, specifically in areas 
of vascularization and angiogenesis. Constitutively elevated 
levels of HIF-1α protein were detected under normal condi-
tions in OVCAR-3 cells (16). We observed TF3 remarkably 
decreased the expression of HIF-1α in OVCAR-3 cells. 
luciferase reporter assay suggested TF3 inhibited VEGF by 
suppressing HIF-1α. EGCG has been reported to suppress 
breast tumor angiogenesis and growth via inhibiting the activa-
tion of HIF-1α and expression of VEGF (34). Similar functions 
of EGCG were also found in human cervical carcinoma and 
hepatoma cells (35). It suggested that HIF-1α/VEGF might be 
key therapeutic targets for tea polyphenols.
Multiple signaling pathways are involved in the regulation 
of HIF-1α/VEGF. One of them is the Akt signaling pathway. 
Akt signaling pathway has been considered to participate in 
angiogenesis in the neoplastic and non-neoplastic process 
(36). Growth factors, cytokines, and other signaling molecules 
stimulate HIF-1 protein synthesis via activation of Akt 
pathway (16). The activation of Akt pathway starts from the 
phosphorylation of Akt. Then, mTOR can be phosphory-
lated and activated by Akt. Subsequently, activated mTOR 
regulates the phosphorylation and activation of p70S6K 
and 4E-BP1, two known downstream targets of mTOR 
(37). Active p70S6K and 4E-BP1 enhance the translation of 
mRNAs that bear a 5' terminal oligopyrimidine tract, which 
encodes proteins related with the translational apparatus like 
ribosomal proteins, elongation factors and the poly A-binding 
protein (38). In the present study, we proved TF3 markedly 
decreased the phosphorylation of Akt, mTOR, p70S6K, and 
4E-BP1, reduced the expression of HIF-1α and VEGF. This 
effect was potentiated by the PI3K/Akt inhibitor wortmannin 
Figure 6. Proposed mechanism of inhibition of tumor angiogenesis via Akt and Notch-1 pathways.
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and impaired by overexpression of active Akt. This is the 
first report that Akt/mTOR/p70S6K/4E-BP1/HIF-1α/VEGF 
pathway was involved in the anti-angiogenic effect of TF3. 
Recently, some natural compounds have been proven to inhibit 
HIF-1α and VEGF expression by targeting Akt signaling 
pathway. Quercetin, a flavonol found in many fruits and 
vegetables, inhibited angiogenesis mediated human prostate 
tumor growth by targeting VEGFR-2 regulated Akt/mTOR/
p70S6K signaling pathways (39). Silibinin, a natural flavonoid 
extracted from the milk thistle seeds, suppressed HIF-1α 
and mTOR/p70S6K/4E-BP1 signaling pathway in human 
cervical and hepatoma cancer cells (17). Tanshinone IIA, a 
derivative of phenanthrene-quinone from the dried root of 
Salvia miltiorrhiza, regulated breast cancer growth and tumor 
angiogenesis via mTOR/p70S6K/RPS6/4E-BP1-mediated 
repression of HIF-1α and VEGF expression (37). Our study 
was in agreement with the previous studies and suggested that 
Akt/mTOR/p70S6K/4E-BP1/HIF-1α/VEGF pathway was an 
important target for plant-derived nutrients to inhibit tumor 
angiogenesis.
c-Myc is a transcription factor essential for vasculogenesis 
and angiogenesis during development and tumor progression 
(40). Targeting c-Myc/HIF-1α pathway inhibits cancer growth 
and angiogenesis (41).
Akt pathway has an influence on c-Myc (19). ly294002, 
a PI3K/Akt inhibitor, reduced c-Myc expression and regulated 
the degradation of c-Myc via affecting the phosphoryla-
tion status of Thr58 (19). In this study, western blot analysis 
revealed that c-Myc expression and phosphorylation of Akt 
was greatly inhibited by TF3. Hence, we hypothesized that 
Akt/c-Myc/HIF-1α pathway might be related to the anti-
tumor angiogenic effect of TF3. To confirm this hypothesis, 
western blot and luciferase reporter assay were performed. 
Both TF3 and wortmannin inhibited the activation of Akt, 
expression of c-Myc, HIF-1α and VEGF. TF3 and wortmannin 
combination led to a more effective suppression. Conversely, 
transfected cells with plasmid expressing active Akt enhanced 
TF3-resistance of OVCAR-3 cells. These results indicated that 
TF3 inhibited HIF-1α and VEGF via Akt/c-Myc pathway. 
Akt/c-Myc pathway has been discovered to have an impact 
on cellular metabolism, cell proliferation and the cell cycle. 
Akt or c-Myc alone has been proven to regulate angiogenesis 
via HIF-1α/VEGF pathway. In this study, Akt and c-Myc was 
demonstrated to be relevant in stimulating tumor angiogenesis. 
Akt regulated the pro-angiogenic effect of c-Myc through 
modulating the expression of c-Myc. Thus, we discovered 
a novel target pathway responsible for the anti-angiogenic 
activity of TF3 in OVCAR-3 cells.
Notch-1 is important upstream of c-Myc. It modulates 
the expression of c-Myc by directly binding to its promoter. 
Notch-1 is a type I transmembrane receptor. When binding 
to its ligands, metalloproteinase-mediated and γ-secretase-
mediated cleavage is induced. Subsequently, NICD is released 
from plasma membrane, translocated into the nucleus, and 
binds CBF-1/suppressor of hairless/lag-1, mastermind-like-1, 
and p300/CBP, to form a transcriptional coactivator (42). 
Notch-1 is a regulator of tumor angiogenesis (43). Previous 
studies showed overexpression of Notch-1 promoted cell 
growth and tumor angiogenesis in myeloma (44). Whereas, 
Notch-1 antibody presents an adverse effect on tumor growth 
and angiogenesis (45). β-elemene, a sesquiterpene found in a 
variety of plants, has been demonstrated to attenuate angio-
genesis capacity of CD44+ gastric cancer stem-like cells by 
interfering with the expression of Notch-1 (46). Notch-1 
signaling is active in ovarian cancer (47). In the present study, 
we observed TF3 inhibited the cleavage of Notch-1. To verify 
whether there was a link between Notch-1/c-Myc pathway and 
HIF-1α/VEGF pathway, DAPT, a γ-secretase inhibitor was 
used. According to the results, DAPT lowered the expression 
of NICD, c-Myc, HIF-1α and VEGF. It hinted that HIF-1α 
and VEGF were regulated by Notch-1/c-Myc pathway in 
OVCAR-3 cells. Further experiments revealed that TF3 
promoted the repressive effect of DAPT on Notch-1/c-Myc 
pathway. On the contrary, overexpression of NICD hampered 
TF3-trigged inhibition of these proteins. Based on the above 
results, we concluded that TF3 downregulated HIF-1α and 
VEGF partially by suppressing Notch-1/c-Myc pathway. The 
protein level of NICD in TF3 and/or DAPT treated cells was 
control group>TF3 group>DAPT group>TF3+DAPT group, 
while the protein levels of c-Myc and HIF-1α were control 
group>DAPT group>TF3 group>TF3+DAPT group. This 
inconsistence could be explained by TF3 suppressing c-Myc/
HIF-1α pathway not only via Notch-1, but also other targets 
(for example, Akt pathway). Besides, the combination of TF3 
and DAPT failed to cause an additive effect on decreasing 
VEGF secretion, implying Notch-1/c-Myc pathway might only 
play a subordinate role in the anti-angiogenic function of TF3.
MAPK pathways regulate many cellular activities, 
including angiogenesis. MAPKs are activated by the dual 
phosphorylation of neighboring threonine and tyrosine resi-
dues in response to various extracellular stimuli (48). ERK, 
JNK and p38 are three major groups of MAPKs. ERKs are 
often activated by growth signals, while JNK and p38 are 
often initiated by stress-responsive signaling (48). FoxO1 is 
a forkhead transcription factor which specifically regulates 
a nonredundant, but overlapping set of angiogenesis- and 
vascular remodeling-related genes (49). FoxO1 contains 
15 consensus phosphorylation sites for the MAPK family. It 
has been demonstrated that ERK and p38 directly regulated 
the transcriptional activity of FoxO1 via phosphorylation (50). 
Similarly, JNK-dependent phosphorylation of FoxO proteins 
results in nuclear accumulation and enhanced transcriptional 
activity (51). In the former studies, EGCG inhibited tumor 
angiogenesis through inactivating ERK1/2 in human colon 
carcinoma cells (52) and human pancreatic tumors (53). EGCG 
increased the activity of p38, but not ERK 1/2 in OVCAR-3 
cells (54). In HUVECs, inhibition of PI3K/AKT and MEK/
ERK pathways enhanced the anti-angiogenic effects of 
EGCG through activation of FoxO transcription factors (48). 
However, we did not observe any effect of TF3 on ERK1/2, 
JNK or p38 in this case. This result implicated that although 
TF3 and EGCG shared some anti-angiogenic targets, they had 
their specific targets. This might be related to their molecular 
structures. TF3 possesses a benzotropolone skeleton that is 
formed from co-oxidation of EGCG and ECG, one with a 
vic-trihydroxy moiety and the other with an ortho-dihydroxy 
structure (9). The benzotropolone moiety has been proven to 
be important in the antioxidant activity (55), anti-inflamma-
tory activity (56), anti-peptide transport activity and activating 
AMP-activated protein kinase (57). Thus, we speculated that 
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benzotropolone moiety might also be vital for its anticancer 
activity. Quantitative structure-activity relationship analysis 
should be carried out to investigate this assumption.
In conclusion, this study presented that TF3 had the ability 
to inhibit ovarian cancer cell-induced angiogenesis in vitro and 
in vivo. TF3 exerted this effect through suppression of HIF-1α 
and VEGF. One of the mechanisms is that TF3 inhibited Akt/
mTOR/p70S6K/4E-BP1 pathway. Other mechanisms included 
TF3-mediated inactivation of Akt/c-Myc and Notch-1/c-Myc 
pathways. MAPK pathways were not involved. This study 
provides novel perspectives and potential targets for the 
anticancer activity of TF3 (Fig. 6). Further studies in animal 
models and human trials are needed to evaluate the antitumor 
angiogenic activity of TF3.
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